How can innovative forms of clinical research contribute to deliver affordable cancer care in an evolving health care environment?

被引:41
作者
Burock, Susen [1 ]
Meunier, Francoise [1 ]
Lacombe, Denis [1 ]
机构
[1] EORTC Headquarters, B-1200 Brussels, Belgium
关键词
Pay for performance; Observational cohort studies; Real life data; Clinical trials; Public private partnership; DRUG DEVELOPMENT; TRIALS; VIEW;
D O I
10.1016/j.ejca.2013.05.016
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
As health care costs are constantly rising and governments are reforming their healthcare systems there is an urgent need to reshape the European clinical research landscape. To bridge the translational gap extensive research to understand the mechanism of the agents and of the disease has to be performed and the real benefit of drugs needs to be assessed independently. Furthermore, meaningful data for reimbursement strategies will be a major goal of future clinical trials as well. Therefore, a new integrated model of clinical cancer research is needed to optimise the R&D process. Strategies to ensure that we can gather robust and relevant data about the effectiveness of various healthcare interventions have to be developed to provide optimal patient care within the limits of a healthcare budget. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2777 / 2783
页数:7
相关论文
共 23 条
  • [1] [Anonymous], 2013, World Health Statistics 2012, Part II Highlighted Topics
  • [2] Targeting targeted agents: open issues for clinical trial design
    Bria, Emilio
    Di Maio, Massimo
    Carlini, Paolo
    Cuppone, Federica
    Giannarelli, Diana
    Cognetti, Francesco
    Milella, Michele
    [J]. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2009, 28
  • [3] The price of innovation: new estimates of drug development costs
    DiMasi, JA
    Hansen, RW
    Grabowski, HG
    [J]. JOURNAL OF HEALTH ECONOMICS, 2003, 22 (02) : 151 - 185
  • [4] How Many "Me-Too" Drugs Is Too Many?
    Gagne, Joshua J.
    Choudhry, Niteesh K.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (07): : 711 - 712
  • [5] The Innovative Medicines Initiative: A European Response to the Innovation Challenge
    Goldman, M.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2012, 91 (03) : 418 - 425
  • [6] Evolving Brand-Name And Generic Drug Competition May Warrant A Revision Of The Hatch-Waxman Act
    Grabowski, Henry G.
    Kyle, Margaret
    Mortimer, Richard
    Long, Genia
    Kirson, Noam
    [J]. HEALTH AFFAIRS, 2011, 30 (11) : 2157 - 2166
  • [7] Drug discovery in pharmaceutical industry: productivity challenges and trends
    Khanna, Ish
    [J]. DRUG DISCOVERY TODAY, 2012, 17 (19-20) : 1088 - 1102
  • [8] Can the pharmaceutical industry reduce attrition rates?
    Kola, I
    Landis, J
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) : 711 - 715
  • [9] Phase 0 clinical trials: Recommendations from the task force on methodology for the development of innovative cancer therapies
    Kummar, Shivaani
    Doroshow, James H.
    Tomaszewski, Joseph E.
    Calvert, A. Hilary
    Lobbezoo, Marinus
    Giaccone, Giuseppe
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (05) : 741 - 746
  • [10] Academia-Industry Partnerships: Are we ready for new models of partnership? The point of view of the EORTC, an academic clinical cancer research organisation
    Lacombe, Denis
    Burock, Susen
    Meunier, Francoise
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 (01) : 1 - 7